Treatments and Therapies | Alzheimer's Society

Positive drug trial results of a new treatment for dementia-related psychosis presented at Clinical Trials on Alzheimer’s Disease conference - Alzheimer's Society comment

Researchers presented results from a phase 3 trial of pimavanserin that showed a significant reduction in the risk of relapse into psychosis compared to the placebo.

Alzheimer's Society responds to Biogen, Aducanumab results at Clinical Trials on Alzheimer's Disease Conference (CTAD)

Biogen presented their results on Aducanumab, their newest drug for the treatment of Alzheimer's disease at the CTAD conference 2019 in San Diego, USA.

Biogen Inc. will ask U.S. drug regulators to approve new Alzheimer’s drug, Alzheimer’s Society responds

Biogen Inc. will ask U.S. drug regulators to approve the company’s experimental Alzheimer’s therapy, reviving the nearly abandoned treatment, after a new analysis of data from two failed clinical trials showed promising results.

Biogen to halt late-stage trial of Alzheimer’s dug – Alzheimer’s Society comment

US pharmaceuticals company Biogen and its Japanese partner Eisai have announced they will discontinue a global Phase 3 trial for a promising Alzheimer’s disease treatment, aducanumab.

Namaste care: research update

Malayka Rahman-Amin, Research Translation Manager at Alzheimer's Society, tells us about a therapy for people with advanced dementia, and how her role supports researchers to make a real-world impact.

Stem cells and Alzheimer's disease

Sian Gregory, from our Will to Remember team, has a background with years of research into stem cells. Here Sian reports on some of the latest dementia research involving them.

Exercise-induced hormone may prevent memory loss

New research, published in the Nature journal today, suggests there may be a relationship between the exercise-induced protein hormone irisin and the progression of Alzheimer's disease.

Yale researchers say new compound shows promise in dementia treatment - Alzheimer's Society comment

According to a new study, Yale University researchers have identified a drinkable cocktail of molecules that interferes with a first step of Alzheimer’s disease.

Understanding whether anticholinergic drugs to treat bladder problems increases risk of dementia

Research project: Using healthcare databases to understand whether anticholinergic bladder drugs influence dementia risk

Can leptin, the anti-obesity hormone, protect brain cells?

Research project: Investigations into the neuroprotective actions of leptin in tau-related synaptic dysfunction.

Research news in brief: Winter 2018

We take a look at some bite-sized news stories from dementia research, winter 2018.

27 November 2018

Finding an NHS dentist

Explore the dental services available to people with dementia through the NHS.

BAN2401: Hope or Hokum?

Following the announcement that a drug trial showed positive results, we take a look at whether the hype is justified and what the results mean.

01 September 2018